Melanoma is a tumor produced by the malignant transformation of melanocytes. Although this usually occurs on the skin, it can arise in other locations where neural crest cells migrate such as the GI tract and brain.

Lymphoma is the most common blood cancer. The two main forms of lymphoma are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) Marginal zone lymphomas (MZLs) are a group of indolent (slow- growing) B-cell NHLs, which account for approximately eight percent of all NHL cases.

Gynecomastia is defined as enlargement of the glandular tissue in male breasts. Gynecomastia is an uncommon manifestation during treatment with a tyrosine kinase inhibitor, such as dasatinib or imatinib, with only a few reports of this occurrence. We describe a case highlighting this event and propose a potential treatment.

Human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) are major health issues within Louisiana. In 2018, Louisiana ranked 4th in the nation for both HIV and AIDS case rates.

Squamous cell carcinoma (SCC) is the second most common cutaneous malignancy after basal cell carcinoma and has an increasing prevalence worldwide.

Percutaneous endoscopic gastrostomy (PEG) feeding is vital to maintain enteral nutrition during the treatment of head and neck cancers. PEG placement is a relatively safe procedure with low risk of complications.

Each year, more than 50,000 new cases of oropharyngeal cancers are diagnosed.1 Studies have shown that early detection and treatment can help improve patient outcomes. If the cancer is localized, the 5-year survival rate is 86% as compared to 36% in those with metastases.

Sarcomas are a rare type of tumor that account for about one percent of all cancer, arises from mesenchymal cells, and are often asymptomatic until they become very large. Post-radiation sarcomas, or radiation induced sarcomas (RIS), are rare complications of radiotherapy that occur within a previously irradiated field over a latency period of 10 to 15 years.

Isolated extramedullary ALL relapse is rare and represents a challenging clinical scenario as patients with extramedullary disease are often excluded from clinical trials and there is limited data regarding optimal treatment strategies. Inotuzumab ozogamicin is a targeted therapy approved for relapsed ALL, and two case reports suggest extramedullary disease may respond to inotuzumab alone.

Breast and gynecologic cancer screenings are available to a wide population of female patients through insurance providers and various support programs, however these cancers remain prevalent in our population today. In the context of screening availability, barriers leading to late/end-stage breast and gynecologic cancers must be explored. This report aims to highlight unique barriers that contribute to presentation with late-stage breast and gynecologic cancer in women of low socioeconomic status.